News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Clinical Study From Rational Therapeutics Doubles Response Rate in Patients With Advanced Lung Cancer; Personalized Treatment for Lung Cancer Comes of Age


10/8/2012 10:14:02 AM

LONG BEACH, Calif.--(BUSINESS WIRE)--Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD®) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics (http://www.rational-t.com) and the MemorialCare Todd Cancer Institute (Long Beach, CA) and published in the October issue of Anticancer Research.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES